Related content

Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection

By Bendet N.   Scapa E.   Cohen O.   Bloch O.   Aharoni D.   Ramot Y.   Weiss M.   Halevi A.   Rapoport M. J.  

Scandinavian Journal of Gastroenterology, Vol. 39, Iss. 7, 2004-07 ,pp. : 650-656

Informa Healthcare

Access to resources Recommend Favorite

Potentiation and prolongation of the insulinotropic action of glucagon-like peptide 1 by methyl pyruvate or dimethyl ester of l-glutamic acid in a type 2 diabetes animal model

By Cancelas Jesús   Villanueva-Peñacrrillo María   Valverde Isabel   Malaisse Willy  

Endocrine Journal, Vol. 16, Iss. 2, 2001-11 ,pp. : 113-116

Humana Press, Inc

Access to resources Recommend Favorite

Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus

By Gallwitz Baptist  

Treatments in Endocrinology, Vol. 4, Iss. 6, 2005-01 ,pp. : 361-370

Adis International

Access to resources Recommend Favorite

Suppression by Exendin(9-39)amide of Glucagon-Like Peptide-1 Insulinotropic Action in Rats Infused with Dimethyl Ester of Succinic Acid

By Cancelas J.   Villanueva-Peñacarrillo M.L.   Valverde I.   Malaisse W.J.  

Endocrine Journal, Vol. 15, Iss. 3, 2001-08 ,pp. : 283-285

Humana Press, Inc

Access to resources Recommend Favorite

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus

By Hogan Andrew   Gaoatswe Gadintshware   Lynch Lydia   Corrigan Michelle   Woods Conor   O’Connell Jean   O’Shea Donal  

Diabetologia, Vol. 57, Iss. 4, 2014-04 ,pp. : 781-784

Springer Publishing Company

Access to resources Recommend Favorite